AQST
Price
$3.08
Change
-$0.02 (-0.65%)
Updated
Jan 30 closing price
Capitalization
383.26M
39 days until earnings call
HROW
Price
$30.68
Change
-$1.01 (-3.19%)
Updated
Jan 31, 11:08 AM (EDT)
Capitalization
467.85M
41 days until earnings call
Ad is loading...

AQST vs HROW

Header iconAQST vs HROW Comparison
Open Charts AQST vs HROWBanner chart's image
Aquestive Therapeutics
Price$3.08
Change-$0.02 (-0.65%)
Volume$1.05M
Capitalization383.26M
Harrow
Price$30.68
Change-$1.01 (-3.19%)
Volume$1.2K
Capitalization467.85M
AQST vs HROW Comparison Chart
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. HROW commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a StrongBuy and HROW is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (AQST: $3.08 vs. HROW: $31.69)
Brand notoriety: AQST and HROW are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 69% vs. HROW: 86%
Market capitalization -- AQST: $383.26M vs. HROW: $467.85M
AQST [@Pharmaceuticals: Other] is valued at $383.26M. HROW’s [@Pharmaceuticals: Other] market capitalization is $467.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than AQST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 6 TA indicator(s) are bullish while HROW’s TA Score has 2 bullish TA indicator(s).

  • AQST’s TA Score: 6 bullish, 3 bearish.
  • HROW’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, AQST is a better buy in the short-term than HROW.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а -1.60% price change this week, while HROW (@Pharmaceuticals: Other) price change was -5.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.16%. For the same industry, the average monthly price growth was +2.97%, and the average quarterly price growth was -6.86%.

Reported Earning Dates

AQST is expected to report earnings on May 13, 2025.

HROW is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.16% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($468M) has a higher market cap than AQST($383M). HROW YTD gains are higher at: -5.544 vs. AQST (-13.483). HROW has higher annual earnings (EBITDA): 9.95M vs. AQST (1.18M). HROW has more cash in the bank: 82.8M vs. AQST (23.9M). AQST has less debt than HROW: AQST (33.3M) vs HROW (191M). HROW has higher revenues than AQST: HROW (130M) vs AQST (50.6M).
AQSTHROWAQST / HROW
Capitalization383M468M82%
EBITDA1.18M9.95M12%
Gain YTD-13.483-5.544243%
P/E RatioN/A39.53-
Revenue50.6M130M39%
Total Cash23.9M82.8M29%
Total Debt33.3M191M17%
FUNDAMENTALS RATINGS
AQST vs HROW: Fundamental Ratings
AQST
HROW
OUTLOOK RATING
1..100
5563
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10034
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6438
P/E GROWTH RATING
1..100
10010
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for HROW (83) in the Pharmaceuticals Other industry. This means that AQST’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is significantly better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew significantly faster than AQST’s over the last 12 months.

HROW's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew similarly to AQST’s over the last 12 months.

HROW's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as AQST (64) in the Pharmaceuticals Major industry. This means that HROW’s stock grew similarly to AQST’s over the last 12 months.

HROW's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew significantly faster than AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTHROW
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 30 days ago
85%
Bullish Trend 24 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
80%
View a ticker or compare two or three
Ad is loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSQAX16.830.19
+1.14%
Invesco MSCI World SRI Index A
VSFIX25.130.24
+0.96%
Federated Hermes Clover Small Value IS
PINPX14.01N/A
N/A
Principal Diversified Intl R5
LGOTX33.33N/A
N/A
Lord Abbett Growth Opportunities R5
TSOPX13.50N/A
N/A
Nuveen International Res Eq Prmr

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and ACET have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
-0.65%
ACET - AQST
26%
Poorly correlated
-1.33%
CPHI - AQST
26%
Poorly correlated
+5.81%
SUPN - AQST
26%
Poorly correlated
-0.79%
SNDL - AQST
24%
Poorly correlated
+4.62%
HROW - AQST
24%
Poorly correlated
-2.04%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-2.04%
AMRX - HROW
33%
Loosely correlated
-1.72%
ORGO - HROW
29%
Poorly correlated
-0.79%
RMTI - HROW
26%
Poorly correlated
+1.47%
EBS - HROW
25%
Poorly correlated
+2.87%
IRWD - HROW
24%
Poorly correlated
-38.17%
More